scholarly journals Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Diabetes Care ◽  
2016 ◽  
Vol 39 (11) ◽  
pp. e199-e200 ◽  
Author(s):  
Christof M. Kazda ◽  
Ying Ding ◽  
Ronan P. Kelly ◽  
Parag Garhyan ◽  
Chunxue Shi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Diabetes Care ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

scholarly journals Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Diabetes Care ◽  
2015 ◽  
Vol 39 (7) ◽  
pp. 1241-1249 ◽  
Author(s):  
Christof M. Kazda ◽  
Ying Ding ◽  
Ronan P. Kelly ◽  
Parag Garhyan ◽  
Chunxue Shi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

scholarly journals Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Diabetes Care ◽  
2019 ◽  
Vol 43 (1) ◽  
pp. 161-168 ◽  
Author(s):  
Jeremy H. Pettus ◽  
David D’Alessio ◽  
Juan P. Frias ◽  
Eric G. Vajda ◽  
James D. Pipkin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Efficacy And Safety ◽  
Glucagon Receptor ◽  
Metformin Monotherapy ◽  
Glucagon Receptor Antagonist ◽  
Dose Ranging

scholarly journals Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

2017 ◽  
Vol 19 (11) ◽  
pp. 1521-1528 ◽  
Author(s):  
Cristina B. Guzman ◽  
Xiaotian M. Zhang ◽  
Rong Liu ◽  
Arie Regev ◽  
Sudha Shankar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Liver Fat ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

2017 ◽  
Vol 19 (8) ◽  
pp. 1071-1077 ◽  
Author(s):  
Christof M. Kazda ◽  
Juan Frias ◽  
Irene Foga ◽  
Xuewei Cui ◽  
Cristina B. Guzman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Ambulatory Blood Pressure ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 73-OR ◽  
Author(s):  
JEREMY PETTUS ◽  
ERIC G. VAJDA ◽  
JAMES PIPKIN ◽  
GRETCHEN WILLIAMSON ◽  
MIRIAM A. ZANGMEISTER ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document